Screening for Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) among Endometrial Cancer Patients

Heather Hampel, Wendy Frankel, Jenny Panescu, Janet Lockman, Kaisa Sotamaa, Daniel Fix, Ilene Comeras, Jennifer La Jeunesse, Hidewaki Nakagawa, Judith A. Westman, Thomas W. Prior, Mark Clendenning, Pamela Penzone, Janet Lombardi, Patti Dunn, David E. Cohn, Larry Copeland, Lynne Eaton, Jeffrey Fowler, George Lewandowski, Luis Vaccarello, Jeffrey Bell, Gary Reid, and Albert de la Chapelle

Abstract

Endometrial cancer is the most common cancer in women with Lynch syndrome. The identification of individuals with Lynch syndrome is desirable because they can benefit from increased cancer surveillance. The purpose of this study was to determine the feasibility and desirability of molecular screening for Lynch syndrome in all endometrial cancer patients. Unselected endometrial cancer patients \( (N = 543) \) were studied. All tumors underwent microsatellite instability (MSI) testing. Patients with MSI-positive tumors underwent testing for germ line mutations in \( MLH1, MSH2, MSH6, \) and \( PMS2. \) Of 543 tumors studied, 118 (21.7\%) were MSI positive (98 of 118 MSI high and 20 of 118 MSI low). All 118 patients with MSI-positive tumors had mutation testing, and nine of them had deleterious germ line mutations (one \( MLH1, \) three \( MSH2, \) and five \( MSH6. \)) In addition, one case with an MSI-negative tumor had abnormal MSH6 immunohistochemical staining and was subsequently found to have a mutation in \( MSH6. \) Immunohistochemical staining was consistent with the mutation result in all seven truncating mutation–positive cases but was not consistent in two of the three missense mutation cases. We conclude that in central Ohio, at least 1.8\% (95\% confidence interval, 0.9-3.5\%) of newly diagnosed endometrial cancer patients had Lynch syndrome. Seven of the 10 Lynch syndrome patients did not meet any published criteria for hereditary nonpolyposis colorectal cancer, and six of them were diagnosed at age >50. Studying all endometrial cancer patients for Lynch syndrome using a combination of MSI and immunohistochemistry for molecular prescreening followed by gene sequencing and deletion analysis is feasible and may be desirable.

Introduction

Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer or HNPCC) is the most common form of hereditary colorectal cancer, accounting for 1 of every 45 cases of colorectal cancer (1). However, its frequency among endometrial cancer patients is less well studied. Although reported cancer risks for individuals with Lynch syndrome vary by population and gene, it seems that women with this syndrome have a higher risk of endometrial cancer than of colorectal cancer (2–4). Given this risk information, it might be expected that the proportion of endometrial cancer cases accounted for by Lynch syndrome would be the same or greater than that of colorectal cancer. It is important to identify endometrial cancer patients with Lynch syndrome because they require annual colonoscopy given their high risk for developing subsequent colorectal cancers (5), whereas endometrial cancer patients who do not have Lynch syndrome can follow the American Cancer Society guidelines for colorectal cancer screening (colonoscopy every 10 years beginning at age 50). In addition, women with Lynch syndrome may have many additional family members who are also at risk for Lynch syndrome and who could benefit from genetic testing and increased cancer surveillance if they have also inherited the condition.

The true frequency of Lynch syndrome among all newly diagnosed cases of endometrial cancer is difficult to assess from most studies because they either determined the frequency of Lynch syndrome among cases with microsatellite instability (6–9) and among subsets of cases with early-onset disease, metachronous colorectal cancer, or positive family history (10–14), or they did not include complete testing (including deletion analysis) for all known mismatch repair genes (15, 16). Judging from all these previous studies, the frequency of Lynch syndrome among endometrial cancer patients could be as low as 0\% and as high as 10\%. Two of the largest series studied to date have found that 1.8\% (8 of 441; 12 mutations were found total, but this included four variants of uncertain significance) and 2.1\% (11 of 519) of endometrial cancer patients have Lynch syndrome (14, 16). One of these studies (16) did not include testing for \( MLH1 \) mutations at all, whereas mutations in this gene accounted for 6 of 11 mutations found in the other study (14). The latter series of patients was from Finland (14), a country with two well-known founder mutations in \( MLH1, \) which could lead to a different frequency of Lynch syndrome.

Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

H. Hampel had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Requests for reprints: Albert de la Chapelle, The Ohio State University, 420 West 12th Avenue, 646 TMBF, Columbus, OH 43210. Phone: 614-688-4781; Fax: 614-688-4772; E-mail: Albert.deLaChapelle@osumc.edu.

©2006 American Association for Cancer Research. doi:10.1158/0008-5472.CAN-06-1114
To clarify the frequency of Lynch syndrome among all newly diagnosed cases of endometrial cancer, we did testing in a large series of patients from a defined geographic region unselected for age at diagnosis or family history. We compared the strategies of microsatellite instability (MSI) testing, immunohistochemical staining, and family history as methods to characterize patients with endometrial tumors caused by Lynch syndrome. This is the largest series of endometrial cancer patients studied to date and involves the most complete genetic testing (sequencing of MLH1, MSH2, and MSH6 and testing for large deletions or rearrangements of MLH1, MSH2, MSH6, and PMS2) for the diagnosis of Lynch syndrome.

Materials and Methods

Patients. Individuals eligible for the study were those newly diagnosed with adenocarcinoma of the endometrium regardless of age or family history of cancer at three participating hospital systems. These hospitals perform the vast majority of all operations for endometrial cancer in the Columbus, OH metropolitan area (population is 1.5 million).

The research protocol and consent form were approved by full review of the Institutional Review Board in accord with an assurance filed with and approved by the U.S. Department of Health and Human Services at all participating hospitals in 1999. From January 1, 1999 to December 4, 2003, 1,154 patients were diagnosed with endometrial cancer at the three hospital systems. Eligible patients were approached by their physician and a protocol nurse, and written informed consent was obtained allowing MSI testing of their tumor. If their tumor was found to be MSI positive, this initial consent also permitted additional genetic testing of their tumor and blood sample to determine whether or not they had Lynch syndrome. In total, 588 of 1,154 (50.9%) eligible patients consented to the study and provided family history information, a 10- to 20-mL EDTA blood sample, and released a paraffin-embedded tumor block. Twenty-four patients were removed from the study because they had insufficient tumor samples, leaving 564 patients on the study. This report is based on the completed analyses of 543 patients (mean age = 60.9 years; range, 17-94 years). The remaining 21 patients had not completed testing at the time of this report.

Race information was self-reported by the study participants for National Cancer Institute reporting purposes. The patients were largely Caucasian (95%); thus, minorities were underrepresented in this study based on the 2000 U.S. census report for Ohio.2

Patients with endometrial sarcomas or squamous cell carcinomas were not eligible for this study. The vast majority of patients had endometrioid adenocarcinoma (421 of 543, 77.5%) followed by adenosquamous and adenosquamous with squamous metaplasia (49 of 543, 9.0%). There were 27 patients with serous or papillary serous histology (5.0%), 24 with mixed histology (4.4%), 15 with clear cell histology (2.8%), 5 with mucinous adenocarcinomas (0.9%), and 2 with adenocarcinoma NOS (0.4%).

Patients found to have Lynch syndrome received full genetic counseling and signed a second informed consent allowing clinical confirmation of their mutation on a new blood sample.

Samples. DNA and RNA were extracted from the blood by standard methods. The histology of the tumor was reevaluated, an area containing no tumor cells (i.e., normal tissue) was marked on the block. The proportion of tumor cells in material used for DNA extraction exceeded 40% in all cases and was generally >80%. Additionally, an area containing no tumor cells (i.e., normal tissue) was marked on the block. Material from tumor and normal tissue was obtained by microdissection.

Analytic strategy. All 543 tumors were analyzed for MSI because more than two thirds of endometrial cancers among Lynch syndrome patients exhibit this characteristic (17). All 118 tumors with MSI and a subset of 211 MSI-negative tumors underwent immunohistochemical staining and evaluation. If one of the mismatch repair proteins is absent in a tumor, this indicates that the corresponding gene is not producing functional or stable protein. The 118 MSI-positive cases and 9 MSI-negative cases with abnormal immunohistochemical staining underwent mutation testing (Fig. 1). Mutations in MLH1, MSH2, and MSH6 account for >95% of known Lynch syndrome–associated mutations (18). All MSI-positive cases underwent (a) sequencing of MLH1, MSH2, and MSH6; (b) multiplex ligation–dependent probe assay (MLPA) of MLH1, MSH2, MSH6, and PMS2 in search of deletions and duplications (19, 20); (c) immunohistochemical staining for the four mismatch repair proteins; and (d) methylation analysis of the MLH1 promoter (21). The MSI-negative cases with abnormal immunohistochemical staining received testing only for the gene(s) corresponding to the protein(s) absent in the tumor. See Supplementary Table S1 for the overall results of the 118 MSI-positive cases.

In an effort to identify mismatch repair–deficient tumors missed by MSI, two subsets of MSI-negative tumors were studied by immunohistochemical staining for the mismatch repair proteins. First, among the first 401 cases accrued, a subset of MSI-negative cases (n = 46) was chosen meeting one of the following criteria: (a) diagnosis under age 50, (b) synchronous or metachronous endometrial and colorectal cancer primaries, or (c) a first-degree relative with colorectal or endometrial cancer diagnosed at any age. This group was intentionally biased to be more likely to represent cases of Lynch syndrome that were missed by MSI. In addition, after all patients had been accrued to the study, we made a concerted effort to perform immunohistochemical staining on as many MSI-negative cases as possible. Due to logistics, this included all of the cases diagnosed at the main study site (Ohio State University) with enough available tissue (we could re-obtain these tumor blocks) and any of the outside cases that were processed after June 2004. These cases received immunohistochemical staining for all four proteins (with the exception of PMS2 in the cohort of 46). In the end, this heterogeneous group of 211 MSI-negative patients who received immunohistochemical staining included 46 patients selected because they were more likely to have Lynch syndrome, 159 OSU patients, and 6 patients from the other two study sites. Only nine patients (9 of 211, 4.3%) were found to have an abnormal immunohistochemical staining result and were subjected to sequencing and MLPA of the gene(s) corresponding to the protein(s) that were absent in the tumor if possible. A germ line mutation was found in one of these cases; this case we describe as being missed by MSI. This patient was among the 46 selected based on the criteria listed above.

Molecular methods. All assay reactions described below that required thermal cycling (PCR and PCR product purification) and electrophoresis of fluorescently labeled PCR fragments (MSI analysis and sequencing, MLPA) were done with the 96-well GeneAmp PCR System 9700 and with the ABI Prism 310 or 3130 capillary DNA analyzers, respectively (Applied Biosystems, Foster City, CA).

Microsatellite instability. MSI testing was done by genotyping two quasimonomorphic markers (BAT25 and BAT26) and three to four polymorphic markers (D2S123, DSS346, D18S69, and/or D17S250) in tumor and unaffected tissue (blood or endometrium). A consensus panel has recommended the use of a five-marker panel (all of the markers listed above except D18S69; ref. 22). The genotypes were amplified in multiplex fashion with 4 μL HotStarTaq Master Mix (Qiagen GmbH, Hilden, Germany), 10 pmol per primer, and 6 ng genomic DNA in an 8-μL reaction. The thermal cycling conditions were as follows: 11-minute hold at 95°C, 1-minute hold at 96°C, 10 cycles at 94°C for 30 seconds, 56°C for 30 seconds, and 70°C for 1 minute followed by 20 cycles at 90°C for 30 seconds, 56°C for 30 seconds, 70°C for 1 minute, a 30-minute hold at 60°C and a final hold at 4°C indefinitely. The resulting fluorescently labeled fragments were electrophoresed, and the markers’ stability status was analyzed with the Genotyper or GeneMapper software (Applied Biosystems).

The markers were considered unstable when an allele was present in the tumor but not in unaffected tissue. Tumors with two or more unstable markers are MSI high; tumors with one unstable marker are MSI low; tumors with no unstable markers are MSI negative (22). It is important to distinguish MSI-high from MSI-low tumors because this may be indicative of the gene in which the germ line mutation occurs (with MSI-low tumors more common among MSH6 gene mutation carriers; ref. 17).

Immunohistochemical staining. Immunoperoxidase staining was done on formalin-fixed, paraffin-embedded tissue as previously described (23).
The primary antibodies were MLH1 (1:10; BD Biosciences PharMingen, San Diego, CA), MSH2 (1:200; EMD Biosciences, La Jolla, CA), MSH6/GTBP (1:300; BD Biosciences PharMingen), and PMS2 (C20, 1:400; Santa Cruz Biotechnology, Santa Cruz, CA and later 1:50; BD Biosciences PharMingen). Positive and negative controls stained appropriately, and any convicing nuclear staining was considered positive.

**Methylation of the MLH1 promoter.** The majority of all mismatch repair–deficient sporadic endometrial carcinomas are caused by hyper-methylation of the MLH1 promoter (14). We studied the methylation of the MLH1 promoter with the aim of determining whether methylation analysis might be used routinely to triage Lynch syndrome from non-Lynch syndrome tumors that exhibit loss of MLH1 protein on immunohistochemical staining.

First, tumor DNA (2 μg) was treated with sodium bisulfite according to published protocols. Using the bisulfite-treated DNA, in which only the unmethylated cytosines were converted into uracil, we assessed methylation at two different areas of the promoter referred to as the H and D regions.

The H region, located −710 to −576 bp upstream of the translation start site, was studied by methylation-specific PCR (24). We used the primers 5'-ACGTTTTATTAGGGTCGCGC-3' (sense) and 5'-AAACCCTATACCTAATCTATCGCCG-3' (antisense). A 134-bp and/or 130-bp PCR fragment was generated in a 25-μL reaction using 2 μL of bisulfite-treated DNA with a mixture containing 67 mM Tris-HCl, 16.6 mM (NH₄)₂SO₄, 0.0175 μL 2-mercaptoethanol (Bio-Rad Laboratories, Hercules, CA), 1 mM of each deoxynucleotide triphosphate (dNTP; Roche Diagnostics, Indianapolis, IN), 1.25 μL of DMSO (Fisher Scientific, Fair Lawn, NJ), 500 μmol/L of each primer, 1 unit of Taq polymerase (Roche Diagnostics), and 6.7 mmol/L of fresh MgCl₂ (Applied Biosystems). PCR conditions were as follows: 95°C for 3 minutes; then 35 cycles of 95°C for 30 seconds, 60°C for 30 seconds, and 72°C for 30 seconds; and finally, 3 minutes at 72°C. The PCR products were visualized on a 3% agarose gel. If a band was seen at 130 bp, the sample was considered methylated in the H region.

The D region, located −377 to −156 bp upstream of the translation start site, was analyzed by the combined bisulfite restriction analysis (25). The target of the analysis was a BstUI restriction endonuclease cleavage site that consists of two tandemly organized CpG sites (CGCG). We used primers 5'-GTTAGATTATTTAGTAGGTTAGTATAAGTT-3' (sense) and 5'-ACCAAT-CAAATTTTCTACTCTATAA-3' (antisense). With unmethylated DNA, a 221-bp PCR fragment was generated in a 50-μL reaction using 2 μL of bisulfite-treated DNA with a mixture containing a 1 × dilution of 10× PCR buffer (Applied Biosystems), 0.2 mmol/L of each dNTP (Roche Diagnostics), 500 μmol/L of each primer, 2 units of AmpliTaq Gold DNA Polymerase (Applied Biosystems), and 2 mmol/L of fresh MgCl₂ (Applied Biosystems). PCR conditions were as follows: 95°C for 10 minutes; then 45 cycles of 95°C for 30 seconds, 53°C for 30 seconds, and 72°C for 60 seconds; and finally, 5 minutes at 72°C. The PCR products were digested by BstUI (New England Biolabs, Ipswich, MA) for 4 hours at 60°C and separated on a 3% agarose gel. If bands were seen at 120 and 100 bp, the sample was considered methylated in the D region.

**Mutation detection.** To search for germ line mutations, DNA (from blood or occasionally from normal endometrium) was directly sequenced using primers described previously (15, 16, 26) and/or alternative primers (shown in Supplementary Table S2). Common polymorphisms are described

![Flow diagram of the analytical strategy and main results of the study.](image-url)
in numerous sequence variation databases, such as the University of Utah Genome Center SNP database, that are present in various annealing sites of the established primers (15, 16, 26). The alternative primers were designed and implemented to avoid preferentially amplifying a single allele, thus potentially missing mutations. The sequencing of MLH1, MSH2, and MSH6 covered the promoter regions (MLH1 and MSH2 only), exons, and intronic regions adjacent to all splice sites in all 118 patients with MSI-positive tumors. The fluorescently labeled sequencing products were purified and electrophoresed. The sequences were analyzed for variations with the Sequencher (Gene Codes Corp., Ann Arbor, MI) software.

MLPA was used to search for large deletions in the MLH1 and MSH2 genes and in the MSH6 and PMS2 genes as described by the kit's manufacturer (Medical Research Council Holland, Amsterdam, the Netherlands; refs. 20, 27) and analyzed with GeneMapper software. The MLH1 and MSH2 MLPA test was completed for 101 of 118 patients with MSI-positive tumors (11 failed and 6 were not completed due to insufficient DNA). The MSH6 and PMS2 MLPA test was completed for 97 of 118 patients with MSI-positive tumors (14 failed and 7 were not completed due to insufficient DNA).

Mutations leading to a truncated or unstable protein are considered clearly deleterious and are diagnostic of the Lynch syndrome; these include frameshift, nonsense, and splice site mutations as well as large deletions and rearrangements. Mutations that result in a full-length protein with one amino acid substituted for another are known as missense mutations and are a priori considered variants of uncertain significance. Missense changes in the mismatch repair genes are common, and it is challenging to assess their pathogenicity (28, 29). As published elsewhere, we conducted extensive functional analyses of missense mutations in MSH6. As published elsewhere, we conducted extensive functional analyses of missense mutations in MSH6 (30), and MLH1 (31). The clinical significance of all missense mutations identified was assessed using these results and principles described previously (1), and families were counseled about the uncertain significance of these results.

Statistical methods. Statistical analysis was conducted using R software. χ² tests with Yates’ continuity correction were applied to compare the frequency of Lynch syndrome and MSH6 mutations between the endometrial and colorectal cancers. Whenever the expected count was < 5, Fisher’s exact test was applied instead of the χ² test. Two-sided 95% confidence intervals (95% CI) of the proportions were estimated using Wilson score method with continuity correction, as described by Newcombe (32).

Results

Accrual. During the period January 1, 1999 through December 4, 2003, 588 patients were accrued to the study; 21 were removed for insufficient tumor material, leaving 564 patients on study. At the time of this data analysis, 543 of them had completed molecular analysis. The study included patients seen by the eight gynecologic oncologists in the three major hospital systems in Columbus, OH. Only 39 patients declined the study, with decliners numbering between 1 and 28 at the various sites. The main reasons for declining the study were lack of interest, no at-risk family members, not wanting to worry about genetics or involve family, and concerns about insurance risks.

MSI. MSI high was seen in 98 of 543 (18.1%), and MSI low was seen in another 20 of 543 (3.7%) tumors. In contrast to our experience with colorectal cancer where no mutations were found among patients with MSI-low tumors (1), mutations were found in two patients whose tumors were MSI low. Of the six MSH6 mutation carriers’ tumors, one was a MSI-negative case (“missed by MSI”); two were MSI low; and three were MSI high. All four carriers of mutations in MLH1 or MSH2 had MSI-high tumors at five of five markers tested. All results of testing for the 118 MSI-positive cases are included in Supplementary Table S1.

Immunohistochemical analysis. Immunohistochemical staining had an excellent sensitivity to detect MSI high in that 90 of 96 tumors showing high MSI (two cases did not have immunohistochemical staining) also showed abnormal immunohistochemical staining for at least one of the four proteins (93.8% sensitivity). In contrast to MSI high, as expected, abnormal immunohistochemical staining was less prevalent among MSI-low cases: 13 of 20 (65%) tumors had an absent protein. The sensitivity of immunohistochemical staining to pinpoint the affected gene in cases with deleterious mutations was high: two of three for MSH2, one of one for MLH1, and five of six for MSH6. The two cases in which immunohistochemical staining did not correctly identify the gene in which a germ line mutation was found were both from patients with missense mutations.

To address the clinical utility of MSI versus immunohistochemical staining as a primary screening method, we did immunohistochemical staining on 211 MSI-negative cases (described in Materials and Methods). The vast majority (202 of 211, 95.7%) had all successful stains present in the tumor as expected. Only nine MSI-negative cases had any stain absent on immunohistochemical staining, including two cases with MLH1 and PMS2 absent, two cases with MSH2 and MSH6 absent, two cases with MSH6 only absent, two cases with MLH1 only absent, and one with MSH2 only absent. Eight of the nine cases received full sequencing of the suspect gene(s), and seven of the nine cases received MLPA of the suspect gene(s) (see Supplementary Table S1). One germ line MSH6 mutation was identified (case 140): this patient’s tumor had absence of MSH6 only on immunohistochemical staining. It is possible that the two cases with incomplete testing also have germ line mutations diagnostic of Lynch syndrome. The cases with absence of protein but without germ line mutations may be due to mutations missed by the detection methods, missed promoter methylation, the presence of biallelic somatic mutations in the tumors, or a false immunohistochemical staining result.

We cannot fully address the sensitivity and specificity of MSI and immunohistochemical staining to detect Lynch syndrome because we did not perform mutation testing in the 202 cases that were MSI negative and had normal immunohistochemical staining. We can, however, assess the clinical utility of MSI and immunohistochemical staining based on the 327 cases that received both tests. Abnormal MSI results led to mutation testing for 118 cases, and these cases were tested for three mismatch repair genes (354 genes sequenced and subjected to MLPA). Using MSI alone, we would have detected 9 of the 10 cases known to have Lynch syndrome in this cohort. Abnormal immunohistochemical staining results would have led to genetic testing for 112 cases; however, at most, two genes would have needed tested (224 genes sequenced and subjected to MLPA). Eight of the 10 Lynch syndrome cases would have been detected using immunohistochemical staining as the initial screen, and 130 less genes would have been sequenced and subjected to MLPA.

Methylation of the MLH1 promoter. The results are shown in Supplementary Table S1. Methylation testing was successful at the H region in 118 of 118 and at the D region in 116 of 118 MSI-positive tumors. Among 84 tumors that did not stain for MLH1

8 http://www.genome.utah.edu/genesnps.
10 S. Ollila et al. Pathogenicity of MSH2 missense mutations is typically associated with impaired repair capability of the mutated protein, 2006, submitted for publication.
11 http://cran.r-project.org/.
protein, which were tested successfully for methylation at both regions, 79 displayed methylation in at least one of the two regions (71 H^D^+ and 8 H^-D^-). This confirms that epigenetic silencing of the MLH1 gene through acquired methylation was likely the cause of the absent MLH1 immunohistochemical staining. Totally, only five tumors with absent MLH1 staining were not methylated; one of these had a germ line mutation in MLH1.

Conversely, when assessing the correlation of methylation status at the two regions with the presence or absence of MLH1 on immunohistochemical staining, we found 5 of 13 (38.5%) H^-D^- tumors had the presence of MLH1 protein on immunohistochemical staining compared with only 6 of 73 (8.2%) H^D^+ tumors with presence of MLH1 protein on immunohistochemical staining.

**Deleterious mutations.** There were 10 probands found to have a deleterious mutation causative of Lynch syndrome whose essential characteristics are shown in Table 1. None of these patients had previously been diagnosed with Lynch syndrome; however, one of the patients (case 1020) was also among our case series of colorectal cancer (1) because she was diagnosed with both cancers during the enrollment period for these studies. Nine patients are Caucasian, one is African American. Mutations in MSH6 (n = 6) were more common than mutations in MLH1 (n = 1) and MSH2 (n = 3) combined. Of note, 3 of 10 probands had large gene deletions underscoring the importance of deletion/rearrangement testing in this patient population. Two missense mutations (Thr^39Pro in MSH2 and Glu^1193Lys in MSH6) were deemed deleterious based on extensive functional studies (31)^7^, and the three patients who had one of these mutations were diagnosed with Lynch syndrome.

**Missense mutations.** Twenty-nine missense mutations were identified in 27 (27 of 543, 5.0%) of the endometrial cancer patients (Table 2). Eight missense mutations (accounting for 12 patients: MLH1 Val213Met, Lys618Ala, Arg659Gln, and Val716Met; MSH2 Gly322Asp; and MSH6 Gly281Ser) were deemed deleterious based on their frequency in controls and other functional evidence (30, 31)^7^, and the three patients who had one of these mutations were also found to have a deleterious mutation. Two missense mutations (accounting for three patients) were determined to be deleterious as noted above. There are 13 patients with missense mutations for which the clinical significance is still unknown.

Of interest, the Val878Ala missense mutation was found in one of 140 population controls (0.7%). This mutation has been reported multiple times in the literature with some suggesting it could be deleterious (33–35), some uncertain (12, 36–39), and some that it is a polymorphism (40, 41). The largest study involving this mutation reported this mutation in more than 70% of the patients with missense mutations (accounting for three patients) were determined to be deleterious as noted above. There are 13 patients with missense mutations for which the clinical significance is still unknown.

### Table 1. Deleterious mutations detected

<table>
<thead>
<tr>
<th>Case no.</th>
<th>Age</th>
<th>Race</th>
<th>Histology</th>
<th>Amsterdam*</th>
<th>Bethesda †</th>
<th>Family history of cancer and age at diagnosis (FDR and SDR from side of family with mutation if known)</th>
</tr>
</thead>
<tbody>
<tr>
<td>59092</td>
<td>39</td>
<td>White</td>
<td>ASM</td>
<td>N</td>
<td>N</td>
<td>Mom; skin &lt;50</td>
</tr>
<tr>
<td>862</td>
<td>50</td>
<td>White</td>
<td>E</td>
<td>Y</td>
<td>N</td>
<td>Mom; CRC x 3-7, Sister; Gyn d.28, Mat half-sister; CRC and endo 50, Mat uncle CRC and bladder d.60, Mat uncle CSU d.70s, Mat grandma CSU d.50s</td>
</tr>
<tr>
<td>1020</td>
<td>44</td>
<td>Black</td>
<td>AS</td>
<td>Y</td>
<td>Y</td>
<td>Proband, CRC 46; Mom, CRC 49 and 62; Mat uncle, gastric and CRC 40s</td>
</tr>
<tr>
<td>537</td>
<td>45</td>
<td>White</td>
<td>ASM</td>
<td>N</td>
<td>N</td>
<td>Brother, thyroid 28; Pat aunt, CRC or gastric 82; Pat grandma, gastric 5; Pat grandpa, Hodgkin 60s</td>
</tr>
<tr>
<td>140</td>
<td>47</td>
<td>White</td>
<td>E</td>
<td>N</td>
<td>N</td>
<td>Proband, CRC 46; Daugther, Endo 48; Sister, endo 60; Sister, CRC 47; Brother, bladder 58; Dad, gastric 51; Pat uncle, CSU?</td>
</tr>
<tr>
<td>55251</td>
<td>68</td>
<td>White</td>
<td>E</td>
<td>N</td>
<td>N</td>
<td>Proband, CRC 46; Daugther, Endo 48; Sister, endo 60; Sister, CRC 47; Brother, bladder 58; Dad, gastric 51; Pat uncle, CSU?</td>
</tr>
<tr>
<td>475</td>
<td>69</td>
<td>White</td>
<td>ASM</td>
<td>Y</td>
<td>Y</td>
<td>Proband, CRC 46; Daugther, Endo 48; Sister, endo 60; Sister, CRC 47; Brother, bladder 58; Dad, gastric 51; Pat uncle, CSU?</td>
</tr>
<tr>
<td>345</td>
<td>60</td>
<td>White</td>
<td>E</td>
<td>N</td>
<td>N</td>
<td>Mom, mouth; Mat aunt, lung 50s, Pat uncle, CSU 60s</td>
</tr>
<tr>
<td>501</td>
<td>60</td>
<td>White</td>
<td>E</td>
<td>N</td>
<td>N</td>
<td>Brother, skin 60; Niece, bone 20s</td>
</tr>
<tr>
<td>553</td>
<td>64</td>
<td>White</td>
<td>M</td>
<td>N</td>
<td>N</td>
<td>Dad, lymphoma 67; Pat uncle, CSU 20s, Pat aunt, breast 70s, Mat aunt, CML 80s, Mat aunt, breast 60s, Mat uncle, CSU (9CRC) 70s</td>
</tr>
</tbody>
</table>

Mean age 54.6

**NOTE:** —, not applicable.

Abbreviations: E, endometrioid adenocarcinoma; AS, adenosquamous carcinoma; ASM, adenocarcinoma with squamous metaplasia; M, mixed endometrioid and clear cell adenocarcinoma; FDR, first-degree relatives; SDR, second-degree relatives; CRC, colorectal cancer; Gyn, gynecologic cancer; Endo, endometrial cancer; CSU, cancer site unknown; CML, chronic myelogenous leukemia; N, no; Y, yes; d., died.

*Indicates whether or not the patient met Amsterdam II criteria (43).
†Indicates whether or not the patient met revised Bethesda guidelines (45).
‡Number of microsatellite markers unstable out of total number tested.

---

Cancer Res 2006; 66: (15). August 1, 2006 7814 www.aacrjournals.org

Downloaded from cancerres.aacrjournals.org on April 28, 2017. © 2006 American Association for Cancer Research.
The 95% CIs for the 1.8% frequency among endometrial cancer difference was not significant with a Ohio population (2.2% or 23 of 1,066; ref. 1) using the among newly diagnosed colorectal cancer patients in the same patients (1.8% or 10 of 543) was compared with the frequency of Lynch syndrome among newly diagnosed endometrial cancer patients were from 0.9% to 3.5%. The 95% CI for the 2.2% frequency among colorectal cancer patients ranged from 1.4% to 3.3%.

The number of MSH6 mutations found among the endometrial cancer patients was compared with the number of MSH6 mutations found among colorectal cancer patients (1). The difference in the frequency of deleterious MSH6 mutations found in endometrial cancer patients (8 of 543) compared with colorectal cancer patients (3 of 1,066) was significant ($P = 0.009$, Fisher’s exact test).

Discussion

There were several important findings in this study. First, the frequency of Lynch syndrome seems to be similar to that seen in colorectal cancer patients from the same geographic area. At least 1.8% (95% CI, 0.9-3.3%) of all endometrial cancer patients have Lynch syndrome versus 2.2% (95% CI, 1.4-3.3%) of colorectal cancer patients (1). Two other large studies of endometrial cancer patients have found that 1.8% and 2.1% of unselected endometrial cancer patients have Lynch syndrome (14, 16), nearly identical to our findings in both endometrial cancer (this study) and colorectal cancer (1). It is important to consider that our finding of 1.8% must represent a minimum. Some mutation carriers may have been overlooked for a variety of reasons. In addition, because we only counted two of the missense mutations identified in this study as deleterious, there is a high likelihood that we have actually underestimated the frequency of Lynch syndrome. Missense mutations pose an extreme clinical challenge. Even with excellent research resources, which are not typically available clinically, the significance of these mutations often remains uncertain.

It needs to be determined whether or not this frequency should warrant routine screening of all endometrial cancer patients for Lynch syndrome. These women are at increased risk for developing other Lynch syndrome malignancies, most notably colorectal cancer, and would benefit from increased colonoscopic surveillance.
6 of 10 patients would not have been detected using this strategy. Nevertheless, we reject the study found that 8.6% of all endometrial cancer patients diagnosed (4.9%; 95% CI, 1.6-12.8%) have Lynch syndrome. Another recent reduction in effort). Of the 81 patients diagnosed under age 50, 4 have only required genetic testing for 13 patients (an 89% cancer surveillance. There is evidence that endometrial cancer seems that methylation at the D region may be more predictive promoter as a routine test to exclude Lynch syndrome. It appears not extensive enough to favor or rule out methylation of the MLH1 promoter as a routine test to exclude Lynch syndrome. It seems that methylation at the D region may be more predictive of the loss of MLH1 protein than the H region.

A common practice is to screen for Lynch syndrome among cancer patients diagnosed with Lynch syndrome as has been published previously (47). In the present study, there were one MSI-negative case and two MSI-low cases among the endometrial cancer patients with Lynch syndrome when compared with colorectal cancer patients with Lynch syndrome. Cost-benefit analysis data will be necessary to consider these screening options on a large, public health scale. It would certainly reduce costs if mutation analysis was not necessary in cases exhibiting methylation of the MLH1 promoter. However, our data are not extensive enough to favor or rule out methylation of the MLH1 promoter as a routine test to exclude Lynch syndrome. It seems that methylation at the D region may be more predictive of the loss of MLH1 protein than the H region.

Another important finding is the lower level of MSI in colorectal cancer patients with Lynch syndrome when compared with colorectal cancer patients with Lynch syndrome as has been published previously (47). In the present study, there were one MSI-negative case and two MSI-low cases among the endometrial cancer patients diagnosed with Lynch syndrome. This is different from the MSI findings in our colon cancer series, where there were...

### Table 2. Sequence changes of unknown significance detected

<table>
<thead>
<tr>
<th>Case no.</th>
<th>Age</th>
<th>Race</th>
<th>Amsterdam*</th>
<th>Bethesda</th>
<th>MSI †</th>
<th>Gene</th>
<th>Nucleotide</th>
<th>Mutation</th>
<th>Impression</th>
<th>Population frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>1020</td>
<td>44</td>
<td>Black</td>
<td>N</td>
<td>Y</td>
<td>5/5</td>
<td>MLH1</td>
<td>c.637G&gt;A</td>
<td>p.Val213Met</td>
<td>P</td>
<td>(31) 0/280; 3/114†</td>
</tr>
<tr>
<td>904</td>
<td>68</td>
<td>White</td>
<td>N</td>
<td>Y</td>
<td>3/5</td>
<td>MLH1</td>
<td>c.977T&gt;C</td>
<td>p.Val326Ala</td>
<td>UV</td>
<td>ND</td>
</tr>
<tr>
<td>55251</td>
<td>68</td>
<td>White</td>
<td>N</td>
<td>Y</td>
<td>3/5</td>
<td>MLH1</td>
<td>c.1852_1853delAAinsG</td>
<td>p.Lys618Ala</td>
<td>P</td>
<td>(31) 0/280</td>
</tr>
<tr>
<td>132</td>
<td>47</td>
<td>White</td>
<td>Y</td>
<td>Y</td>
<td>5/5</td>
<td>MLH1</td>
<td>c.1852_1853delAAinsG</td>
<td>p.Lys618Ala</td>
<td>P</td>
<td>(31) 0/280</td>
</tr>
<tr>
<td>541</td>
<td>59</td>
<td>White</td>
<td>N</td>
<td>N</td>
<td>3/5</td>
<td>MLH1</td>
<td>c.2066A&gt;G</td>
<td>p.Gln689Arg</td>
<td>UV</td>
<td>0/280</td>
</tr>
<tr>
<td>74</td>
<td>39</td>
<td>White</td>
<td>N</td>
<td>Y</td>
<td>5/5</td>
<td>MLH1</td>
<td>c.2146G&gt;A</td>
<td>p.Val716Met</td>
<td>P</td>
<td>(31) 0/280</td>
</tr>
<tr>
<td>537</td>
<td>45</td>
<td>White</td>
<td>N</td>
<td>Y</td>
<td>2/5</td>
<td>MSH2</td>
<td>c.97A&gt;C</td>
<td>p.Thr33Pro</td>
<td>D</td>
<td>(30) 0/280</td>
</tr>
<tr>
<td>1544</td>
<td>57</td>
<td>White</td>
<td>N</td>
<td>Y</td>
<td>1/5</td>
<td>MSH2</td>
<td>c.1346C&gt;G</td>
<td>p.Asp487Glu</td>
<td>UV</td>
<td>0/280</td>
</tr>
<tr>
<td>1261</td>
<td>70</td>
<td>White</td>
<td>N</td>
<td>N</td>
<td>3/5</td>
<td>MSH2</td>
<td>c.1730T&gt;C</td>
<td>p.Ile577Thr</td>
<td>UV</td>
<td>0/280</td>
</tr>
<tr>
<td>192</td>
<td>38</td>
<td>White</td>
<td>N</td>
<td>N</td>
<td>2/5**</td>
<td>MSH2</td>
<td>c.2503A&gt;C</td>
<td>p.Asn835His</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>313</td>
<td>68</td>
<td>White</td>
<td>N</td>
<td>N</td>
<td>2/5</td>
<td>MSH2</td>
<td>c.383G&gt;T</td>
<td>p.Arg128Leu</td>
<td>P</td>
<td>(32) 0/280</td>
</tr>
<tr>
<td>1493</td>
<td>59</td>
<td>White</td>
<td>N</td>
<td>N</td>
<td>3/5</td>
<td>MSH2</td>
<td>c.1304T&gt;C</td>
<td>p.Leu435Pro</td>
<td>UV</td>
<td>ND</td>
</tr>
<tr>
<td>266</td>
<td>58</td>
<td>White</td>
<td>N</td>
<td>N</td>
<td>4/5</td>
<td>MSH2</td>
<td>c.1868C&gt;T</td>
<td>p.Pro623Leu</td>
<td>P</td>
<td>(32) 0/280</td>
</tr>
<tr>
<td>1123</td>
<td>60</td>
<td>White</td>
<td>N</td>
<td>N</td>
<td>3/5</td>
<td>MSH2</td>
<td>c.2633T&gt;C</td>
<td>p.Val878Ala</td>
<td>UV</td>
<td>1/280</td>
</tr>
<tr>
<td>1228</td>
<td>54</td>
<td>White</td>
<td>N</td>
<td>N</td>
<td>2/5</td>
<td>MSH2</td>
<td>c.2633T&gt;C</td>
<td>p.Val878Ala</td>
<td>UV</td>
<td>1/280</td>
</tr>
<tr>
<td>1493</td>
<td>59</td>
<td>White</td>
<td>N</td>
<td>N</td>
<td>3/5</td>
<td>MSH2</td>
<td>c.2633T&gt;C</td>
<td>p.Val878Ala</td>
<td>UV</td>
<td>1/280</td>
</tr>
<tr>
<td>56591</td>
<td>83</td>
<td>White</td>
<td>N</td>
<td>N</td>
<td>5/5</td>
<td>MSH2</td>
<td>c.2633T&gt;C</td>
<td>p.Val878Ala</td>
<td>UV</td>
<td>1/280</td>
</tr>
<tr>
<td>509</td>
<td>83</td>
<td>White</td>
<td>N</td>
<td>N</td>
<td>3/5</td>
<td>MSH2</td>
<td>c.2641delGinsAAA</td>
<td>p.Gly811delinsLysSer</td>
<td>P (32) 0/280</td>
<td></td>
</tr>
<tr>
<td>1167</td>
<td>69</td>
<td>White</td>
<td>N</td>
<td>N</td>
<td>3/5</td>
<td>MSH2</td>
<td>c.3442G&gt;C</td>
<td>p.Gly1148Arg</td>
<td>UV</td>
<td>0/280</td>
</tr>
<tr>
<td>501</td>
<td>60</td>
<td>White</td>
<td>N</td>
<td>N</td>
<td>3/5</td>
<td>MSH2</td>
<td>c.3577G&gt;A</td>
<td>p.Glu1193Lys</td>
<td>D (32) 0/280</td>
<td></td>
</tr>
<tr>
<td>553</td>
<td>59</td>
<td>White</td>
<td>N</td>
<td>N</td>
<td>2/5</td>
<td>MSH2</td>
<td>c.3577G&gt;A</td>
<td>p.Glu1193Lys</td>
<td>D (32) 0/280</td>
<td></td>
</tr>
<tr>
<td>1038</td>
<td>61</td>
<td>White</td>
<td>N</td>
<td>N</td>
<td>3/5</td>
<td>MSH2</td>
<td>c.3674C&gt;T</td>
<td>p.Thr1225Met</td>
<td>UV</td>
<td>ND</td>
</tr>
<tr>
<td>702</td>
<td>67</td>
<td>White</td>
<td>N</td>
<td>N</td>
<td>2/5</td>
<td>MSH2</td>
<td>c.4001+10_4001+13delTAAC</td>
<td>—</td>
<td>UV</td>
<td>ND</td>
</tr>
</tbody>
</table>

**Indicates whether or not the patient met Amsterdam II criteria (43). †Indicates whether or not the patient met revised Bethesda guidelines (45). *Number of microsatellite markers unstable out of total number tested. ‡Number of alleles with the mutation from a set of 106 or 140 Caucasian controls except where noted. ††Frequency of mutation among a set of 57 African-American controls. *Patient with two missense mutations. **Patient was originally MSI negative, but repeat MSI testing following an abnormal immunohistochemical staining result was positive.
no mutation carriers with MSI-low tumors. This finding may explain how MSI missed one mutation carrier in this study. The differences in MSI levels between the endometrial cancer patients with Lynch syndrome may be directly owing to the larger number of MSH6 mutations found in this population. There was a 5-fold increased likelihood of finding a deleterious mutation in MSH6 among endometrial cancer patients when compared with colorectal cancer patients, and this difference was statistically significant. This supports previous findings suggesting a higher risk for endometrial cancer for MSH6 mutation carriers than is found for MLH1 and MSH2 mutation carriers (4) and a lower level of MSI among endometrial cancers from MSH6 mutation carriers (17).

Acknowledgments

Received 3/24/2006; revised 5/9/2006; accepted 5/16/2006.

Grant support: NIH grants CA67941 and CA61058 and Andrew McGiffin Barford Memorial Fund.

The authors of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Sandhya Liyanarachchi, M.S. for performing the statistical analysis; Ana Adel, B.S. and Imad Elkhawas, B.S. for their technical assistance in the population studies of missense mutations; Robert Pilarski, M.S., Carrie Drovold, M.S., and Rebecca Nagy, M.S. for advice on the article; The Ohio State University Comprehensive Cancer Center (OSU CCC) Pathology Core Facility; Carl Morrison, D.V.M., M.D., Director, Mary Martin, B.A., Supervisor (cutting the tissue), and Jonise Jones, B.S. (immunohistochemical staining) for pathology services; and the OSU CCC Tissue Archive Service; Scott Jewell, Ph.D., Director and Cheryl Reeder, B.A., Supervisor for pulling blocks and coordinating pathology services.

References


Screening for Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) among Endometrial Cancer Patients

Heather Hampel, Wendy Frankel, Jenny Panescu, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/66/15/7810

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2006/08/01/66.15.7810.DC1

Cited articles
This article cites 47 articles, 16 of which you can access for free at:
http://cancerres.aacrjournals.org/content/66/15/7810.full.html#ref-list-1

Citing articles
This article has been cited by 59 HighWire-hosted articles. Access the articles at:
/content/66/15/7810.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.